FI120258B - Bentsamidderivat, kompositioner innehållande denna derivat och användning av den - Google Patents
Bentsamidderivat, kompositioner innehållande denna derivat och användning av den Download PDFInfo
- Publication number
- FI120258B FI120258B FI964031A FI964031A FI120258B FI 120258 B FI120258 B FI 120258B FI 964031 A FI964031 A FI 964031A FI 964031 A FI964031 A FI 964031A FI 120258 B FI120258 B FI 120258B
- Authority
- FI
- Finland
- Prior art keywords
- compound
- formula
- group
- pharmaceutical composition
- atom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/58—Nitro radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
Claims (16)
1. Förening med formeln (I) UL^U ... r5 n« 5 där symbolen Ri betecknar en OH-grupp, varvid de äterstäende symbolerna igen betecknar en H-atom.
2. Farmaceutisk komposition, känneteckna d därav, att den innehäller som aktivt ämne en förening med formeln ^0*1^ ... Rg R, 10 där symbolen Ri betecknar en OH-grupp, varvid de äterstäende symbolerna igen betecknar en H-atom.
3. Farmaceutisk komposition enligt patentkrav 2, kännetecknad därav, att den innehäller som ak- 15 tivt ämne en blandning av föreningen A med formeln OH H j f Π NO,-^ NH-C-^ y H H H där Ri = OH och R2 = R3 = R4 = R5 = H; och föreningen B med formeln ococh3 -—N o 1 H NO,—NH-C-fZ/-9 H H
4. Farmaceutisk komposition enligt patentkrav 2 eller 3 för oral administrering tili en patient, kanne-t e c k n a d därav, att den ytterligare innehäller ett 5 fuktmedel.
5. Farmaceutisk komposition enligt patentkrav 4, kännetecknad därav, att minst ett fuktmedel är valt ur en grupp, som bestär av anjonaktiva ytaktiva me-del.
6. Farmaceutisk komposition enligt patentkrav 4, kännetecknad därav, att fuktmedlet är valt ur en grupp, som bestär av sockerestrar, polyoxietylen, poly-oxipropylen, anhydrohexitolderivat, fettalkanolamider, fett-aminoxider, sackaros, mannitol, sorbitol, lecitiner, poly-15 vinylpyrrolidoner, fettsyraestrar, glycerider av sackaros, estrar av xylos, polyoxietylenglycerider, fettsyraestrar och polyoxietylenetrar av fettalkoholer och polyoxietylenfettsyraestrar av sorbitan, polyoxietylenestrar av sorbitanfett-syror, glyceridpolyglysider, estrar av alkoholpolyglysider 20 och blandningar av ovannämnda.
7. Farmaceutisk komposition enligt nägot av före-gäende patentkrav, kännetecknad därav, att den innehäller ett stärkelsederivat.
8. Farmaceutisk komposition enligt patentkrav 7, 25 kännetecknad därav, att den innehäller karboxi- metylstärkelse eller ett sait därav.
9. Farmaceutisk komposition enligt patentkrav 4, kännetecknad därav, att den innehäller högst 20 vikt-% ytaktivt medel i förhällande tili vikten av ak- 30 tivt ämne (aktiva ämnen) och högst 20 vikt-% stärkelsede- rivat i förhällande tili vikten av aktivt ämne eller akti-va ämnen.
10. Galeniskt preparat för oral administerering tili en patient, kännetecknat därav, att det 5 innehäller en kärna omfattande en komposition, som inne-häller: en effektiv mängd av en förening med formeln (I) r5 a4 10 där symbolen Ri betecknar en OH-grupp, varvid de äterstäende symbolerna igen betecknar en H-atom; eventuellt i blandning med föreningen B med formeln OCOCHj -N O I_ H no2——NH- c-<y3~H H H 15 ett fuktmedel och ett stärkelsederivat varvid nämnda komposition har en fukthalt under 25 vikt-%.
11. Galeniskt preparat enligt patentkrav 10, k ä n-20 netecknat därav, att den innehäller karboximetyls- tärkelse eller ett sait därav.
12. Salva för behandling sjukdomar i undermagen, kännetecknad därav, att den innehäller: en effektiv mängd av en förening med formeln (I) .XX..LÄ..... ΓΊ R5 n, där symbolen Fy betecknar en OH-grupp, varvid de äterstäende symbolerna igen betecknar en H-atom; 5 eventuellt i blandning med föreningen B med for meln OCOCHj -N 0 I H I I 11 no2—i!^ ^—nh-c-\_J/~h H H och ett fuktmedel.
13. Salva enligt patentkrav 12, kännetecknad 10 därav att den innehäller ett stärkelsederivat.
14. Förening med formeln (I) Rs r4 där symbolen Ri betecknar en OH-grupp, varvid de äterstäende symbolerna igen betecknar en H-atom, för an-15 vändning som antiparacitiska medel, antibakteriella medel, antifungala medel eller antivirala medel.
15. Blandning av föreningen A med formeln (I) ... r5 r« där Ri = OH och R2 = R3 = R4 = R5 = H; 5 och föreningen B med formeln QCOCHj -N O I H I I 11 J~C_ NOz—^d1-NH^C- H H för användning som antiparacitiska medel, antibak-teriella medel, antifungala medel eller antivirala medel.
16. Livsmedelskomposition, kännetecknad 10 därav, att det som konserveringsmedel innehäller en effektiv mängd av ett aktivt ämne med formeln (I) r5 där symbolen Ri betecknar en OH-grupp, varvid de äterstäende symbolerna igen betecknar en H-atom; eventuellt en förening B med formeln QCOCHj -N 0 I H I i 11 no2——nh-c-\_y/ H H H 5 och eventuellt ett stärkelsederivat.
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/227,033 US5387598A (en) | 1994-04-13 | 1994-04-13 | Composition and galenic formulation suitable for combatting affections of the lower abdomen |
US22703394 | 1994-04-13 | ||
US30140794 | 1994-09-08 | ||
US08/301,407 US5578621A (en) | 1994-09-08 | 1994-09-08 | Benzamide derivatives |
US38385595A | 1995-02-06 | 1995-02-06 | |
US38385595 | 1995-02-06 | ||
PCT/EP1995/001334 WO1995028393A1 (en) | 1994-04-13 | 1995-04-11 | Benzamide derivative, compositions containing said derivative and use thereof |
EP9501334 | 1995-04-11 |
Publications (3)
Publication Number | Publication Date |
---|---|
FI964031A FI964031A (sv) | 1996-10-08 |
FI964031A0 FI964031A0 (sv) | 1996-10-08 |
FI120258B true FI120258B (sv) | 2009-08-31 |
Family
ID=27397680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FI964031A FI120258B (sv) | 1994-04-13 | 1996-10-08 | Bentsamidderivat, kompositioner innehållande denna derivat och användning av den |
Country Status (24)
Country | Link |
---|---|
EP (1) | EP0755386B1 (sv) |
JP (1) | JP3224395B2 (sv) |
KR (2) | KR100373081B1 (sv) |
CN (1) | CN1072654C (sv) |
AP (1) | AP645A (sv) |
AT (1) | ATE218557T1 (sv) |
AU (1) | AU689582B2 (sv) |
BG (1) | BG62932B1 (sv) |
BR (1) | BR9507371A (sv) |
CA (1) | CA2187110C (sv) |
CZ (1) | CZ287002B6 (sv) |
DE (1) | DE69526936T2 (sv) |
DK (1) | DK0755386T3 (sv) |
ES (1) | ES2161201T3 (sv) |
FI (1) | FI120258B (sv) |
HU (1) | HUT77404A (sv) |
NZ (1) | NZ284800A (sv) |
OA (1) | OA10463A (sv) |
PL (1) | PL186504B1 (sv) |
PT (1) | PT755386E (sv) |
RU (1) | RU2140915C1 (sv) |
SI (1) | SI0755386T1 (sv) |
SK (1) | SK281949B6 (sv) |
WO (1) | WO1995028393A1 (sv) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5968961A (en) | 1997-05-07 | 1999-10-19 | Romark Laboratories, L.C. | Pharmaceutical compositions of tizoxanide and nitazoxanide |
US5856348A (en) * | 1994-09-08 | 1999-01-05 | Romark Laboratories, L.C. | Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide |
CA2467321A1 (en) | 2004-05-14 | 2005-11-14 | Paul J. Santerre | Polymeric coupling agents and pharmaceutically-active polymers made therefrom |
JP4956427B2 (ja) | 2004-07-21 | 2012-06-20 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | レンチウイルスベクターおよびその使用 |
UA90864C2 (en) | 2004-09-09 | 2010-06-10 | Ромарк Лебораториз, Л.К. | Halogenated benzamide derivatives |
EP1976516B9 (en) | 2006-01-09 | 2013-10-30 | Romark Laboratories, L.C. | Viral hepatitis treatment |
MX2010001358A (es) | 2007-08-03 | 2010-04-09 | Romark Lab Lc | Compuestos de tiazolida sustituidos con alquilsulfonilo. |
CA2761876C (en) * | 2009-05-12 | 2017-01-03 | Romark Laboratories L.C. | Haloalkyl heteroaryl benzamide compounds |
KR20170141830A (ko) | 2009-06-26 | 2017-12-26 | 로마크 레버러토리즈, 엘.씨. | 인플루엔자를 치료하기 위한 화합물 및 방법 |
DE112010004110T8 (de) | 2009-10-22 | 2012-12-06 | Thomas Julius Borody | Neue parasitentherapie |
CN104094927B (zh) * | 2013-04-02 | 2016-06-01 | 兴邦(武汉)生物科技有限公司 | 一种处理植物的助剂组合物 |
TW201630606A (zh) * | 2015-01-21 | 2016-09-01 | 諾華公司 | 包含局部藥物之蓋崙(galenic)調配物 |
WO2019148293A1 (en) | 2018-02-02 | 2019-08-08 | Interface Biologics, Inc. | Glass formulations comprising steroid dimers and uses thereof |
JP2023524494A (ja) | 2020-05-01 | 2023-06-12 | リップル セラピューティクス コーポレーション | 眼障害を処置するためのヘテロ二量体組成物と方法 |
EP4337200A1 (en) * | 2021-05-28 | 2024-03-20 | Henderson, Theodore | Treatment using an antiviral compound and nitazoxanide |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1306603A (fr) * | 1958-08-14 | 1962-10-19 | Innothera Lab Sa | Dérivés thiazoliques et leur procédé de préparation |
FR716M (sv) * | 1960-08-05 | 1961-08-07 | ||
GB1437800A (en) * | 1973-08-08 | 1976-06-03 | Phavic Sprl | Derivatives of 2-benzamido-5-nitro-thiazoles |
FR2435905A1 (fr) * | 1978-09-13 | 1980-04-11 | Anvar | Nouveaux agents molluscicides derives du benzamido-2 nitro-5 thiazole |
US4315018A (en) * | 1978-12-07 | 1982-02-09 | Rossignol Jean F | Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives |
US4447414A (en) * | 1982-12-21 | 1984-05-08 | Cutter Laboratories, Inc. | Carnivore anthelmintics |
-
1995
- 1995-04-11 CZ CZ19962959A patent/CZ287002B6/cs not_active IP Right Cessation
- 1995-04-11 BR BR9507371A patent/BR9507371A/pt not_active IP Right Cessation
- 1995-04-11 DE DE69526936T patent/DE69526936T2/de not_active Revoked
- 1995-04-11 RU RU96119364A patent/RU2140915C1/ru not_active IP Right Cessation
- 1995-04-11 WO PCT/EP1995/001334 patent/WO1995028393A1/en not_active Application Discontinuation
- 1995-04-11 EP EP95917310A patent/EP0755386B1/en not_active Revoked
- 1995-04-11 CA CA002187110A patent/CA2187110C/en not_active Expired - Lifetime
- 1995-04-11 AP APAP/P/1996/000866A patent/AP645A/en active
- 1995-04-11 JP JP52669395A patent/JP3224395B2/ja not_active Expired - Lifetime
- 1995-04-11 AT AT95917310T patent/ATE218557T1/de not_active IP Right Cessation
- 1995-04-11 AU AU23440/95A patent/AU689582B2/en not_active Ceased
- 1995-04-11 SK SK1307-96A patent/SK281949B6/sk not_active IP Right Cessation
- 1995-04-11 KR KR10-2000-7003874A patent/KR100373081B1/ko not_active IP Right Cessation
- 1995-04-11 KR KR1019960705785A patent/KR100348440B1/ko not_active IP Right Cessation
- 1995-04-11 PT PT95917310T patent/PT755386E/pt unknown
- 1995-04-11 DK DK95917310T patent/DK0755386T3/da active
- 1995-04-11 NZ NZ284800A patent/NZ284800A/en not_active IP Right Cessation
- 1995-04-11 HU HU9602798A patent/HUT77404A/hu unknown
- 1995-04-11 CN CN95192524A patent/CN1072654C/zh not_active Expired - Fee Related
- 1995-04-11 PL PL95316757A patent/PL186504B1/pl not_active IP Right Cessation
- 1995-04-11 ES ES95917310T patent/ES2161201T3/es not_active Expired - Lifetime
- 1995-04-11 SI SI9530607T patent/SI0755386T1/xx unknown
-
1996
- 1996-10-03 BG BG100884A patent/BG62932B1/bg unknown
- 1996-10-04 OA OA60900A patent/OA10463A/en unknown
- 1996-10-08 FI FI964031A patent/FI120258B/sv not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI120258B (sv) | Bentsamidderivat, kompositioner innehållande denna derivat och användning av den | |
MXPA96004483A (en) | Derivatives of benzamide, compositions that contain such derivative and use of the mis | |
US5886013A (en) | Antiviral composition | |
PL193556B1 (pl) | Środek farmaceutyczny | |
CA2015312A1 (en) | Control of protozoal disease | |
AU740022B2 (en) | Pharmaceutical compositions of tizoxanide and nitazoxanide | |
MXPA00010855A (es) | Uso de derivados de benzamida como agentes parasitarios, antibacterianos, antivirales y antifungicos | |
RO118293B1 (ro) | Derivat de benzamida, compozitii continand acest derivat si utilizarea acestuia | |
US20060142243A1 (en) | Use of n-acetyl-d-glucosamine for preparing medicines for urogenital tract infection's treatment and prevention | |
US4333945A (en) | Thiazoline and imidazoline derivatives useful as minor tranquilizers | |
JPH0441127B2 (sv) | ||
AU5785901A (en) | Pharmaceutical compositions of tizoxanide and nitazoxanide | |
JPH09508150A (ja) | B型肝炎の予防または治療のためのチオケテン誘導体の用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Patent granted |
Ref document number: 120258 Country of ref document: FI |
|
MM | Patent lapsed |